Robert Burns

Telix Pharmaceuticals Ltd (NASDAQ:TLX) is the world's most "diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company," according to HC Wainwright. The Telix Pharmaceuticals Analyst: Analyst Robert Burns initiated coverage with a Buy rating and price...

H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ:CATX), a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer treatment. Analyst Robert Burns initiated a Buy rating and a price target of $10. The...

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the...